Tag: Simcere

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Neuro by Comments are Disabled

NANJING, China, Sept. 5, 2024 /PRNewswire/ — On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation…

Continue Reading →